Form 4: Accelerate Diagnostics CFO Receives 37,468 Restricted Stock Units

David Patience, CFO of Accelerate Diagnostics, was granted 37,468 restricted stock units (RSUs) on March 5, 2024, which will vest on April 9, 2024.

Summary

• David Patience, the Chief Financial Officer of Accelerate Diagnostics, Inc. [AXDX], received a grant of 37,468 Employee Restricted Stock Units (RSUs) on March 5, 2024.
• Each RSU represents a contingent right to receive one share of Accelerate Diagnostics' common stock upon vesting.
• The RSUs are scheduled to vest on April 9, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to executive compensation, and does not contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of RSUs to the CFO aligns his interests with those of the shareholders.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance beyond the vesting of the RSUs.

Industry Context

This type of equity compensation is common in the diagnostics industry to incentivize and retain key executives.

Comparison to Industry Standards

• Equity compensation packages for CFOs in the diagnostics industry typically include a mix of stock options, restricted stock units, and performance-based awards.
• The size of the RSU grant is likely determined based on factors such as the CFO's experience, performance, and the company's overall compensation strategy.
• Comparing the grant to similar companies like QuidelOrtho or BioMerieux would provide a better understanding of its relative value.

Stakeholder Impact

• The RSU grant could have a slightly dilutive effect on existing shareholders.

Key Dates